奥乐妥珠单抗

化合物

奥乐妥珠单抗INN:otlertuzumab;开发代号:TRU‐016)是一种靶向CD37[1]人源化单克隆抗体,设计用于治疗癌症。[2]

奥乐妥珠单抗
单克隆抗体
种类?
目标CD37
临床资料
ATC码
  • 未分配
识别信息
CAS号1372645-37-8
ChemSpider
  • none
UNII
化学信息
化学式C4660H7136N1246O1452S30
摩尔质量104,809.42 g·mol−1

该药物由Emergent BioSolutions开发,已进入淋巴瘤慢性淋巴细胞白血病的临床试验。[3]

参考资料

  1. ^ Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S. Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnology Letters. December 2018, 40 (11–12): 1459–1466. PMID 30293139. S2CID 52925605. doi:10.1007/s10529-018-2612-6. 
  2. ^ Otlertuzumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. [2024-03-19]. (原始内容存档 (PDF)于2013-12-13). 
  3. ^ Otlertuzumab. ClinicalTrails.gov. U.S. National Library of Medicine.